Increased Risk of SARS-CoV-2 Infection Clinical Trial
Official title:
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial
This is a randomized controlled trial of the efficacy and safety evaluation of oral administration of Bromhexine hydrochloride for the prevention of SARS-CoV-2 infection and COVID-19 disease in medical personnel assisting patients with a new coronavirus disease
Status | Completed |
Enrollment | 50 |
Est. completion date | August 31, 2020 |
Est. primary completion date | August 9, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age of 18 years or more; 2. Negative test (PCR) for SARS-CoV-2 infection; 3. The absence of clinical manifestations of a respiratory infection; 4. Contact with patients with laboratory and / or clinically confirmed SARS-CoV-2 infection; 5. Signed informed consent to participate in the study. Exclusion Criteria: 1. Intolerance to Bromhexine hydrochloride; 2. Work out of contact with SARS-CoV-2 infection; 3. Non-compliance with the rules for the use of personal protective equipment when working with SARS-CoV-2 infection (the rules for the use of personal protective equipment in accordance with the recommendations of the Ministry of Health of Russia and the internal orders of the Director General of Almazov NMRC, relevant to the dates of research); 4. Pregnancy and the period of breastfeeding; 5. Other circumstances that the researcher considers inappropriate to participate in this study |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Almazov National Medical Research Centre | Saint Petersburg |
Lead Sponsor | Collaborator |
---|---|
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Negative Polymerase Chain Reaction (PCR) | Number of Participants with Negative PCR of SARS-CoV-2 and The Absence of Clinical Manifestations of COVID-19 Infection in individuals taking Bromhexine hydrochloride 4 weeks after randomization. | 4 weeks after randomization | |
Secondary | Number of Participants With Asymptomatic SARS-CoV-2 Infection | Number of Participants with Asymptomatic SARS-CoV-2 Infection | 14 days after last contact | |
Secondary | Number of Participants With Mild, Moderate and Severe COVID-19 Disease | number of participants with mild, moderate and severe COVID-19 disease | 14 days after last contact | |
Secondary | Number of Participants With Adverse Events | Number of Participants with Adverse Events | 14 days after last contact |